文献速递乳腺病理

乳腺病理中的预后与预测参数:病理医生入门指南

Prognostic and predictive parameters in breast pathology: a pathologist's primer.
PubMed 文献 · Mod Pathol · 2020-11-05

本文综述了乳腺癌治疗团队中病理医生所需提供的预后与预测参数,涵盖ER/HER2状态、传统病理参数、基因表达面板(如21基因复发评分)、新辅助治疗后反应及TILs、晚期疾病的BRCA/PIK3CA/PDL-1检测,并说明这些参数如何用于临床治疗决策。

要点

  • ER和HER2状态在所有分期中帮助划分治疗组,预测治疗反应。
  • 早期ER阳性/HER2阴性乳腺癌中,传统病理参数和21基因复发评分指导化疗决策。
  • 晚期疾病中BRCA、PIK3CA和PDL-1状态决定额外治疗选择。

核心结论

  • 病理医生的角色已从诊断扩展到提供不断增多的预后和预测参数,以支持个体化治疗决策。

研究设计与样本

  • 本文为综述,描述乳腺癌预后和预测参数及其在标准病理报告和临床治疗决策中的应用。

主要发现

  • 在所有分期中,ER和HER2状态帮助将乳腺癌分为结局和治疗反应率相似的治疗组。
  • 在早期疾病决策中,传统病理参数如有利的组织学亚型、大小、淋巴结状态和Nottingham分级仍具有临床相关性。
  • 对于ER阳性/HER2阴性乳腺癌,基因表达面板可预测化疗获益,其中21基因复发评分是目前唯一前瞻性验证的预测测试。
  • 在ER阴性乳腺癌亚型中,新辅助治疗反应和肿瘤浸润淋巴细胞(TILs)程度是强大的预后参数。
  • 在四期疾病中,胚系BRCA状态、肿瘤PIK3CA突变状态(ER+转移性疾病)和PDL-1状态(三阴性转移性疾病)用于确定额外治疗选择。

关键数值与推荐

  • 21基因复发评分是目前唯一前瞻性验证的预测测试,用于预测ER阳性/HER2阴性乳腺癌的化疗获益。
  • 临床指南为标准新辅助治疗后残留癌症的高风险患者提供额外治疗选择。
  • ER+转移性疾病中检测肿瘤PIK3CA突变状态,三阴性转移性疾病中检测PDL-1状态,以确定新治疗选项。

临床怎么用

  • 病理报告应包含ER、HER2状态以及传统病理参数如组织学亚型、大小、淋巴结状态和Nottingham分级。
  • 对于ER阳性/HER2阴性早期乳腺癌,可考虑使用21基因复发评分预测化疗获益。
  • 在ER阴性乳腺癌中,评估新辅助治疗反应和TILs程度以提供预后信息。
  • 在晚期疾病中,根据分子标志物如BRCA、PIK3CA和PDL-1状态指导治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The pathologist's role in the breast cancer treatment team has evolved from rendering a diagnosis of breast cancer, to providing a growing list of prognostic and predictive parameters such that individualized treatment decisions can be made based on likelihood of benefit from additional treatments and potential benefit from specific therapies. In all stages, ER and HER2 status help segregate breast cancers into treatment groups with similar outcomes and treatment response rates, however, traditional pathologic parameters such as favorable histologic subtype, size, lymph node status, and Nottingham grade also have remained clinically relevant in early stage disease decision-making. This is especially true for the most common subtype of breast cancer; ER positive, HER2 negative disease. For this same group of breast cancers, an ever-expanding list of gene-expression panels also can provide prediction and prognostication about potential chemotherapy benefit beyond standard endocrine therapies, with the 21-gene Recurrence Score, currently the only prospectively validated predictive test for this purpose. In the more aggressive ER-negative cancer subtypes, response to neoadjuvant therapy and` the extent of tumor infiltrating lymphocytes (TILs) are more recently recognized powerful prognostic parameters, and clinical guidelines now offer additional treatment options for those high-risk patients with residual cancer after standard neoadjuvant therapy. In stage four disease, predictive tests like germline BRCA status, tumor PIK3CA mutation status (in ER+ metastatic disease) and PDL-1 status (in triple negative metastatic disease) are now used to determine additional new treatment options. The objective of this review is to describe the latest in prognostic and predictive parameters in breast cancer as they are relevant to standard pathology reporting and how they are used in breast cancer clinical treatment decisions.

来源:Mod Pathol,查看原文。版权归原作者所有。

引用

  1. Allison KH. Prognostic and predictive parameters in breast pathology: a pathologist's primer. Mod Pathol. 2020. PMID: 33154551. doi:10.1038/s41379-020-00704-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。